康鹏科技：由公司提供原料产品的创新药在美获批上市

Group 1 - The core point of the article is that Kangpeng Technology has successfully supplied the active pharmaceutical ingredient for Dordaviprone, which has been approved in the U.S. for treating recurrent H3K27M mutant diffuse midline glioma in patients aged 1 and above, marking it as the first drug approved for this patient group globally [1][2] - Dordaviprone was initially developed by Chimerix and later acquired by Jazz Pharmaceuticals for over $900 million in March 2025, indicating significant market interest and investment in this innovative treatment [1] - Kangpeng Technology has established a comprehensive service capability covering "custom synthesis—clinical supply—commercial production," which has been built through deep involvement in early-stage drug development [2] Group 2 - The approval of Dordaviprone is seen as a significant achievement for Kangpeng Technology in the pharmaceutical sector, showcasing its "technical accumulation + strategic layout" [2] - The company aims to leverage the global policy benefits for innovative drugs to capture high-value segments of the industry chain through technological barriers [2] - Kangpeng Technology plans to deepen collaboration with multinational pharmaceutical companies to enhance the quality of active pharmaceutical ingredient supply and expand its social responsibility practices, contributing to the availability of medications for patients [2]